Federal Charges for Selling Poppers: What the DOJ's Double-Scorpio Prosecution Means for Sellers, Distributors, Bookkeepers, and Online Retailers

The Department of Justice just secured its first guilty plea in what looks like a new federal enforcement wave against the alkyl nitrites industry. Brett Sandy, the 41-year-old bookkeeper for Austin-based Double-Scorpio, pleaded guilty on April 30, 2026, to two federal conspiracy counts tied to selling more than $8.4 million in poppers products mislabeled as tape cleaner. His coworker Hugo Sanchez is set to enter his own plea on May 26, 2026.

If you sell, manufacture, import, fulfill, market, or even handle the bookkeeping for any product where the label says one thing and the customer knows it means another, the Double-Scorpio case is the federal criminal defense playbook the government will run next. Not just for poppers. For kratom, peptides, novel cannabinoids, research chemicals, and any consumer product positioned with a wink-and-nod label.

The Double-Scorpio plea is not just about one seller. It is a roadmap for how DOJ can charge employees, distributors, and online operators in product-misbranding cases.

What Actually Happened in the Double-Scorpio Case

Sandy pleaded guilty to one count of conspiracy to violate the Food, Drug, and Cosmetic Act and one count of conspiracy to violate the Consumer Product Safety Act under 18 U.S.C. section 371. Maximum exposure is five years per count. The case is United States v. Brett Sandy, 26-cr-00207-RP, before Judge Robert Pittman in the Western District of Texas. Sentencing is set for September 10, 2026. Sandy worked as Double-Scorpio's bookkeeper from January 2019 through February 2025 and spoke directly with customers buying the products to use as a drug. The products had names like Love Potion and Pumpkin Spice Latte. The labels said tape cleaner.

The most damaging fact in the plea is the single sale Sandy admitted to: hundreds of bottles to a customer he understood was going to redistribute the product as a drug at a so-called sexy singles party. That alone resolves the willfulness element under 21 U.S.C. section 333(a)(2), which requires intent to defraud or mislead. The conduct period ending in February 2025 lines up with the FDA's reported search and seizure at Double-Scorpio's offices in March 2025, after which the company announced it had stopped operations. The criminal information filed thirteen months later shows the standard arc: agency raid, document review, federal target letter, charging by information, fast plea.

Who Is Prosecuting These Cases, and the Statutes in Play

Max J. Goldman of the Criminal Division's Fraud Section is prosecuting alongside the Health and Safety Unit. Assistant Attorney General A. Tysen Duva personally announced the plea. FDA Office of Criminal Investigations and the U.S. Consumer Product Safety Commission are the investigating agencies. When a case is run from Main Justice rather than a single U.S. Attorney's Office, the resourcing and the willingness to use creative statutory theories goes up substantially. The Health and Safety Unit was built to prosecute companies and individuals who make and sell dangerous drugs, food, and consumer products. Poppers, kratom, unapproved peptides, illegal vape products, and unauthorized medical devices all sit within its mandate.

The FDCA piece runs through 21 U.S.C. section 331, which prohibits introducing misbranded or unapproved new drugs into interstate commerce. Under 21 U.S.C. section 352, a drug is misbranded if its labeling is false or misleading in any particular. Under 21 U.S.C. section 321(g)(1), a product becomes a drug if it is intended to affect the structure or function of the body, which is exactly what an inhalant marketed for euphoric effect does. A felony violation under 21 U.S.C. section 333(a)(2) requires intent to defraud or mislead and carries up to three years per count. The CPSA piece runs through 15 U.S.C. section 2068, which makes it unlawful to sell consumer products knowingly misbranded or that fail safety rules. Knowing and willful violations under 15 U.S.C. section 2070 carry up to five years per count. Both are charged through 18 U.S.C. section 371.

The decisive element in any federal misbranding prosecution is intent. The government does not need to prove the product was harmful in fact. It needs to prove the defendant knew the label was misleading and acted in furtherance of that scheme. That is why the sexy singles party admission was so consequential.

The core fight in these cases is usually not what the label said. It is what the government can prove the defendant knew the label really meant.

Why a Bookkeeper Got Charged

Sandy was not the owner. He was not the chemist. He was not the marketing director. He kept the books and answered customer calls. He took a federal felony anyway. That is the most important data point in this case for anyone in an adjacent industry.

Federal misbranding law gives prosecutors broad individual reach through two doctrines. The Park responsible corporate officer doctrine under United States v. Park allows criminal liability against any corporate official with authority to prevent the violation. Conspiracy under 18 U.S.C. section 371 sweeps in any participant who joined the agreement and committed any overt act in furtherance. A bookkeeper who tracked sales of mislabeled product, talked to customers, and processed payments satisfies both. Anyone with a corporate email address and a paycheck from a company under FDA criminal investigation scrutiny is potentially exposed: bookkeepers, AR staff, fulfillment managers, customer service reps who knew what the product was actually used for, marketing employees who wrote the copy. The government does not have to charge everyone. It picks the cases that send the message.

This is the part of the case the industry is going to misread. If you assume only owners and principals are at risk in an FDA misbranding case, you are reading the wrong cases. The bookkeeper just took a felony. So can anyone else with knowledge of the scheme.

Florida Exposure for Sellers Based Here or Shipping In

The Western District of Texas brought this case, but nothing in the theory limits it to Texas. For Florida-based sellers, distributors, and fulfillment houses, three layers of exposure matter.

First, federal venue follows the product. Any sale shipped into the Middle District, Southern District, or Northern District of Florida creates venue for federal prosecution. The Middle District of Florida in particular has been aggressive on white collar matters and consumer-product fraud cases, and is a priority district for the DOJ Fraud Division this year.

Second, Florida has its own inhalant statute. Section 877.111 of the Florida Statutes prohibits the sale or distribution of harmful chemical substances to any person knowing or having reasonable cause to believe the substance will be used to induce intoxication. The statute does not require Schedule status. A state prosecutor working alongside federal agents has a clean charging vehicle.

Third, Florida deceptive and unfair trade practices liability under Chapter 501 creates parallel civil exposure. Attorney General civil investigations frequently run alongside or after federal misbranding cases.

Critical Early Mistakes in a Federal Misbranding Investigation

• Talking to FDA OCI agents, CPSC investigators, or postal inspectors without counsel. The interview transcript becomes the first piece of intent evidence.
• Producing documents in response to an administrative subpoena or grand jury subpoena without privilege review. Email threads about product positioning and customer support tickets are where willfulness lives.
• Continuing to ship product after a warning letter, Form 483 observation, or agency visit. Post-warning conduct converts a regulatory matter into a criminal one. The Double-Scorpio conduct-period endpoint lines up with the FDA raid for a reason.
• Cleaning up. Deleting Slack and Teams messages, removing product pages, or wiping a CRM creates obstruction exposure under 18 U.S.C. section 1519 and 18 U.S.C. section 1512 that is often worse than the underlying charge.
• Assuming employee status is protection. Sandy was an employee. Sanchez is an employee. Both are facing felony exposure. Anyone whose name appears on emails, ledgers, or shipping documents is a potential target or material witness.
• Waiting for the indictment. A federal misbranding case is usually charged by information after the defendant has agreed in principle to plead. The window to negotiate that resolution closes well before the public charging document.

By the time a misbranding case becomes public, the government often has shipping data, payment trails, customer calls, and internal messages already lined up.

Defense Angles a Federal Criminal Defense Attorney Will Actually Develop

In a mislabeling case, the labels are not in dispute. What the defendant knew, what the defendant intended, and what the defendant understood about end use is where the case is won or lost.

The marketing record. If product copy, packaging, or labeling was vetted by counsel, a labeling consultant, or a compliance vendor, that paper trail undercuts willfulness. Documented good-faith reliance on advice is a direct counter to the government's deliberate-scheme theory.

The training and role record. For employees, the question is what they were told the product was, what they were told to say to customers, and what visibility they had into marketing and labeling decisions. A customer service rep reading from a script that called the product an industrial cleaner is in a very different position from a bookkeeper who took a call from a buyer at a singles party.

The regulatory history. Warning letters, Form 483 observations, or untitled letters followed by documented remediation support a good-faith defense. Years of open sales without agency contact undercut a deliberate concealment theory.

The customer evidence. What the company knew about end use, from product reviews, support tickets, return data, and analytics, is the strongest intent evidence in most cases. Containing and contextualizing it before agents seize a server or subpoena a payment processor is critical.

Sentencing positioning. Under U.S.S.G. section 2N2.1 for FDCA offenses and section 2B1.1 for fraud-driven enhancements, loss amount, role in the offense, abuse of trust, and obstruction enhancements all swing the guideline range. The 2026 USSC amendments to the section 2B1.1 loss table adjust dollar thresholds for inflation, which directly affects how an $8.4 million revenue figure translates at sentencing. A white collar defense attorney who runs the guidelines and the 3553(a) variance case early preserves options that disappear once the PSR is written.

The strongest defense work in these cases usually happens in the records: role, intent, training, warnings, and what the client actually knew.

Why the 72-Hour Window After First Contact Matters

Federal misbranding cases are slow to build and fast to close. The investigation typically runs for a year or more before any individual learns about it. Once a target or subject gets notice, whether through a federal target letter from FDA OCI, a grand jury subpoena, a CID from HHS-OIG in adjacent healthcare-related matters, or an unexpected agent visit at home, the useful window in any federal investigation defense is short.

Three things have to happen in the first 72 hours. Lock down communications with a written litigation hold across email, Slack, Teams, and every messaging platform. The deleted-text evidence the government recovers later is often more damaging than the underlying conduct. Map exposure and witnesses: who at the company knew what, who has copies of what, who has talked to agents, and who is likely to be approached next. Vendors, payment processors, and outside marketing agencies all become cooperators when grand jury subpoenas hit. Decide cooperation posture deliberately. Voluntary self-disclosure under the DOJ Criminal Division's individual self-disclosure program, or proactive engagement with the AUSA or Fraud Section trial attorney, can convert what looks like an indictment into a non-prosecution agreement or a deferred prosecution agreement in the right circumstances. That decision cannot be made halfway.

If your business has received an FDA inspection observation, a warning letter, a target letter, an HHS-OIG civil investigative demand, or any contact from FDA OCI or CPSC investigators, you are already past the moment when this can be treated as a compliance problem. It is a federal criminal defense problem now.

The first move after contact from federal investigators is not explanation. It is containment, record preservation, and a real defense strategy.

Facing an FDA, FDCA, or Consumer Product Safety Investigation in Florida or Anywhere in the Country?

AMC Defense Law represents owners, executives, employees, bookkeepers, and vendors in federal investigations involving the Food, Drug, and Cosmetic Act, the Consumer Product Safety Act, the Controlled Substances Act, and parallel state statutes. We handle cases from the target letter stage through trial and sentencing, with a strong focus on early intervention before charging decisions are locked in. Our federal criminal defense practice covers healthcare fraud, white collar defense, consumer product fraud, and federal drug charges in Florida and across all federal districts.

Consultations are confidential. If you have received a federal target letter, a grand jury subpoena, a CID from HHS-OIG, an FDA inspection notice, or an unannounced visit from federal agents, the next 72 hours matter. Call us before you respond.

If you or your loved ones have been arrested or are under federal investigation involving poppers, alkyl nitrites, product misbranding, FDA criminal exposure, or related consumer-product charges, call Aaron M. Cohen, 24 hours a day to get help.

This article is for general informational purposes only and is not legal advice. Reading this post does not create an attorney-client relationship with AMC Defense Law. Every case is fact-specific, and you should consult with a qualified federal criminal defense attorney about your particular situation. Prior results do not guarantee a similar outcome.